Axcella Health Inc (AXLA)

Gainers Axcella Health (NASDAQ:AXLA) shares rose 25.5% to $3.0 during Friday's after-market session. The market ...

Axcella Health (NASDAQ:AXLA) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what ...

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Flagship Pioneering spinout Axcella Therapeutics Inc. has promising results from a small Phase 2a study investigating a drug for long Covid.

Avalo Therapeutics (NASDAQ: AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Allarity To Shift Focus On ...

Axcella Health Inc(NASDAQ: AXLA) hasreported topline resultsfrom the Phase 2a study to evaluate the efficacy and ...

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.

One of the first trials aimed at tackling long COVID helped some patients recover from lingering physical and mental fatigue, although the drug developed by Axcella Health Inc failed on the small study's main goal of restoring the normal function of mitochondria - the energy factories of cells. In the 41-patient pilot study released on Tuesday, for three of 21 patients who received the drug, AXA1125, their physical fatigue scores returned to normal levels after 28 days of treatment, Axcella Chief Medical Officer Margaret Koziel said in a phone interview. Others who received the drug also reported physical and mental improvements that were deemed to be statistically significant as shown on a scale developed to measure chronic fatigue, according to the preliminary results, and the drug was shown to be safe and well tolerated.

CAMBRIDGE, Mass., August 02, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

A handful of small companies are working on long Covid treatments — sorely needed tools as the number of those afflicted grows.

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 ...

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced ...

Gainers Cogent Biosciences (NASDAQ:COGT) shares increased by 76.6% to $8.76 during Friday's regular session. As of ...

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID. The company affirmed topline data readout for its Phase 2a Long COVID trial in early Q3 2022 and interim data readout for NASH in late Q3 2022. The company is suspending its Phase 2 clinical trial in OHE (Overt Hepatic Encephalopathy) while exploring potential partnership for the program.

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23 – 26, 2022 both virtually and in-person in Miami, Florida.

Axcella Health (NASDAQ:AXLA) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what ...

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.

Tenet Healthcare's (THC) first-quarter 2022 results are likely to reflect an improvement in adjusted admissions and outpatient admissions.

Moderna's (MRNA) two vaccine candidates, mRNA-1020 and mRNA-1030, target both hemagglutinin and neuraminidase protein for providing better protection against the influenza virus. The company initiates a phase I/II study.

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.

Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth ...